Palvella Therapeutics (PVLA) director awarded 3,000 stock options at $102.19
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Palvella Therapeutics director Tadd S. Wessel received a grant of stock options covering 3,000 shares of common stock. The options have an exercise price of $102.19 per share and expire on June 10, 2036. All 3,000 options are held directly after this transaction. The options vest on the earlier of the first anniversary of the June 10, 2026 grant date or the date of Palvella’s next annual meeting of stockholders, in each case requiring his continued service through the vesting date. This is a compensation-related grant, not an open-market share purchase or sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Wessel Tadd S.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 3,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 3,000 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 3,000 options
Exercise price: $102.19 per share
Underlying shares: 3,000 shares
+2 more
5 metrics
Options granted
3,000 options
Stock Option (Right to Buy) grant on June 10, 2026
Exercise price
$102.19 per share
Conversion or exercise price of granted options
Underlying shares
3,000 shares
Common stock covered by the option grant
Expiration date
June 10, 2036
Option grant expiration
Post-transaction options
3,000 options
Total derivative holdings after this transaction
Key Terms
Stock Option (Right to Buy), grant/award acquisition, annual meeting of stockholders, vesting date
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
grant/award acquisition financial
"transaction_action: grant/award acquisition"
annual meeting of stockholders financial
"the Issuer's next annual meeting of stockholders following the grant date"
vesting date financial
"continued service through the applicable vesting date"
FAQ
What insider transaction did Palvella Therapeutics (PVLA) report for Tadd S. Wessel?
Palvella Therapeutics reported that director Tadd S. Wessel received a grant of stock options for 3,000 shares of common stock. The options were awarded as compensation, not bought on the market, and give him the right to purchase shares at a fixed exercise price.
How many Palvella Therapeutics (PVLA) options were granted and at what price?
Tadd S. Wessel was granted stock options on 3,000 shares of Palvella Therapeutics common stock. The options carry an exercise price of $102.19 per share, meaning he can buy shares at that price once the options vest and are exercisable.
When do Tadd S. Wessel’s Palvella Therapeutics (PVLA) options vest?
The 3,000 stock options granted to Tadd S. Wessel vest on the earlier of the first anniversary of the June 10, 2026 grant date or Palvella’s next annual meeting of stockholders. Vesting is conditioned on his continued service through the applicable vesting date.
When do the newly granted Palvella Therapeutics (PVLA) options expire?
The granted stock options expire on June 10, 2036. After that expiration date, any unexercised options will lapse and no longer allow purchase of Palvella Therapeutics common stock at the fixed $102.19 per share exercise price specified in the award.
How many Palvella Therapeutics (PVLA) options does Tadd S. Wessel hold after this grant?
Following this reported transaction, Tadd S. Wessel holds 3,000 stock options directly. These options relate to 3,000 underlying shares of Palvella Therapeutics common stock and reflect his position from this specific award as reported in the filing.